{"transactions":[{"id":4618358,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:22.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":2311,"price":157.1981,"value":363284.8091,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42808,"source":{"system":"sec-edgar","filing":"0001724097-26-000010","document":"wk-form4_1789506139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724097/000172409726000010/wk-form4_1789506139.xml","form_type":"4"}},{"id":4618357,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:22.000Z","date":"2026-09-11","kind":"tax_withholding","planned":true,"acquired":false,"shares":2709,"price":156.22,"value":423199.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":45119,"source":{"system":"sec-edgar","filing":"0001724097-26-000010","document":"wk-form4_1789506139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724097/000172409726000010/wk-form4_1789506139.xml","form_type":"4"}},{"id":4618356,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:22.000Z","date":"2026-09-11","kind":"grant","planned":true,"acquired":true,"shares":5020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":47828,"source":{"system":"sec-edgar","filing":"0001724097-26-000010","document":"wk-form4_1789506139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724097/000172409726000010/wk-form4_1789506139.xml","form_type":"4"}},{"id":737699,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:07:22.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271074/ownership.xml","form_type":"4"}},{"id":859634,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T23:18:36.000Z","date":"2026-03-04","kind":"gift","planned":false,"acquired":false,"shares":2249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective March 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":42808,"source":{"system":"sec-edgar","filing":"0001724097-26-000007","document":"wk-form4_1772752714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000007/wk-form4_1772752714.xml","form_type":"4"}},{"id":902343,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":7735,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."}],"balance_after":7735,"derivative":{"underlying":"Common Stock","underlying_shares":7735},"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902342,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":44095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":44095,"derivative":{"exercise_price":124.12,"expiration_date":"2036-02-13","underlying":"Common Stock","underlying_shares":44095},"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902341,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":2566,"derivative":{"underlying":"Common Stock","underlying_shares":2566},"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902340,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":4484,"derivative":{"underlying":"Common Stock","underlying_shares":2241},"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902339,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":false,"shares":2133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award."}],"balance_after":6401,"derivative":{"underlying":"Common Stock","underlying_shares":2133},"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902338,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":5378,"price":124.12,"value":667517.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":44881,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902337,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":9968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award."}],"balance_after":50259,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902336,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1385,"price":124.12,"value":171906.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":40291,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902335,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41676,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902334,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1210,"price":124.12,"value":150185.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":39110,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902333,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40320,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902332,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":1151,"price":123.1,"value":141688.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":38079,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":902331,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:49:23.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2133,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":39230,"source":{"system":"sec-edgar","filing":"0001724097-26-000005","document":"wk-form4_1771368557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000005/wk-form4_1771368557.xml","form_type":"4"}},{"id":922926,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-03T23:06:21.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":2437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2437},"source":{"system":"sec-edgar","filing":"0001724097-26-000003","document":"wk-form4_1770159979.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000003/wk-form4_1770159979.xml","form_type":"4"}},{"id":922925,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:06:21.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1368,"price":136.06,"value":186130.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."}],"balance_after":37097,"source":{"system":"sec-edgar","filing":"0001724097-26-000003","document":"wk-form4_1770159979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000003/wk-form4_1770159979.xml","form_type":"4"}},{"id":922924,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:06:21.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":2437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 218 shares purchased on August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":38465,"source":{"system":"sec-edgar","filing":"0001724097-26-000003","document":"wk-form4_1770159979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000172409726000003/wk-form4_1770159979.xml","form_type":"4"}},{"id":1129150,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:06:10.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following May 29, 2025, such that all of the shares shall be fully vested and exercisable on May 29, 2028, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":110000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000950170-25-079711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079711/ownership.xml","form_type":"4"}},{"id":1268286,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026,  2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026,  2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":6725,"derivative":{"underlying":"Common Stock","underlying_shares":2241},"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268285,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and 2,566 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and 2,566 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":5132,"derivative":{"underlying":"Common Stock","underlying_shares":2566},"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268284,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":8534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."}],"balance_after":8534,"derivative":{"underlying":"Common Stock","underlying_shares":8534},"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268283,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":45538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":45538,"derivative":{"exercise_price":117.18,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":45538},"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268282,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1206,"price":116.8688,"value":140943.7728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":35810,"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268281,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37016,"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268280,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1352,"price":116.8487,"value":157979.4424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34775,"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1268279,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:00:12.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2566,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36127,"source":{"system":"sec-edgar","filing":"0000914475-25-000055","document":"wk-form4_1739574004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000055/wk-form4_1739574004.xml","form_type":"4"}},{"id":1272422,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T23:41:59.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":false,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1860},"source":{"system":"sec-edgar","filing":"0000914475-25-000046","document":"wk-form4_1739403711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000046/wk-form4_1739403711.xml","form_type":"4"}},{"id":1272421,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:41:59.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":980,"price":118.274,"value":115908.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $123.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33561,"source":{"system":"sec-edgar","filing":"0000914475-25-000046","document":"wk-form4_1739403711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000046/wk-form4_1739403711.xml","form_type":"4"}},{"id":1272420,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:41:59.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":true,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34541,"source":{"system":"sec-edgar","filing":"0000914475-25-000046","document":"wk-form4_1739403711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000046/wk-form4_1739403711.xml","form_type":"4"}},{"id":1285971,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T22:31:14.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":2436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and will vest as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and will vest as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":2437,"derivative":{"underlying":"Common Stock","underlying_shares":2436},"source":{"system":"sec-edgar","filing":"0000914475-25-000020","document":"wk-form4_1738708264.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000020/wk-form4_1738708264.xml","form_type":"4"}},{"id":1285970,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:31:14.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":1283,"price":152.8728,"value":196135.8024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32681,"source":{"system":"sec-edgar","filing":"0000914475-25-000020","document":"wk-form4_1738708264.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000020/wk-form4_1738708264.xml","form_type":"4"}},{"id":1285969,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:31:14.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":2436,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33964,"source":{"system":"sec-edgar","filing":"0000914475-25-000020","document":"wk-form4_1738708264.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000020/wk-form4_1738708264.xml","form_type":"4"}},{"id":1432946,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-08-15T21:12:01.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":false,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted December 1, 2017 and vested at 25% upon the first anniversary (December 1, 2018) and the  remaining 75% vested in 36 equal monthly installments beginning January 1, 2019."}],"balance_after":0,"derivative":{"exercise_price":73.6,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000914475-24-000193","document":"wk-form4_1723756315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000193/wk-form4_1723756315.xml","form_type":"4"}},{"id":1432945,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-15T21:12:01.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":14100,"price":150.3792,"value":2120346.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31528,"source":{"system":"sec-edgar","filing":"0000914475-24-000193","document":"wk-form4_1723756315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000193/wk-form4_1723756315.xml","form_type":"4"}},{"id":1432944,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-15T21:12:01.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":true,"shares":14100,"price":73.6,"value":1037760.0,"ownership":{"direct":true},"balance_after":45628,"source":{"system":"sec-edgar","filing":"0000914475-24-000193","document":"wk-form4_1723756315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000193/wk-form4_1723756315.xml","form_type":"4"}},{"id":1452077,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-07-18T20:45:11.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":false,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and remaining 75% vesting in 36 equal monthly installments beginning January 1, 2019."}],"balance_after":14100,"derivative":{"exercise_price":73.6,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0000914475-24-000170","document":"wk-form4_1721335504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000170/wk-form4_1721335504.xml","form_type":"4"}},{"id":1452076,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-07-18T20:45:11.000Z","date":"2024-07-16","kind":"sale","planned":true,"acquired":false,"shares":900,"price":150.0411,"value":135036.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31528,"source":{"system":"sec-edgar","filing":"0000914475-24-000170","document":"wk-form4_1721335504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000170/wk-form4_1721335504.xml","form_type":"4"}},{"id":1452075,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-07-18T20:45:11.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":73.6,"value":66240.0,"ownership":{"direct":true},"balance_after":32428,"source":{"system":"sec-edgar","filing":"0000914475-24-000170","document":"wk-form4_1721335504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000170/wk-form4_1721335504.xml","form_type":"4"}},{"id":1514996,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-05-16T20:40:47.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":73.6,"value":1104000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and the remaining 75% vested in 36 equal monthly installments beginning November 1, 2018."}],"balance_after":15000,"derivative":{"exercise_price":73.6,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000914475-24-000121","document":"wk-form4_1715892031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/wk-form4_1715892031.xml","form_type":"4"}},{"id":1514995,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2024-05-16T20:40:47.000Z","date":"2024-05-14","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":73.6,"value":1104000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and the remaining 75% vested in 36 equal monthly installments beginning November 1, 2018."}],"balance_after":30000,"derivative":{"exercise_price":73.6,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000914475-24-000121","document":"wk-form4_1715892031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/wk-form4_1715892031.xml","form_type":"4"}},{"id":1514994,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-16T20:40:47.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":140.2406,"value":2103609.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31528,"source":{"system":"sec-edgar","filing":"0000914475-24-000121","document":"wk-form4_1715892031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/wk-form4_1715892031.xml","form_type":"4"}},{"id":1514993,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-16T20:40:47.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":73.6,"value":1104000.0,"ownership":{"direct":true},"balance_after":46528,"source":{"system":"sec-edgar","filing":"0000914475-24-000121","document":"wk-form4_1715892031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/wk-form4_1715892031.xml","form_type":"4"}},{"id":1514992,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-16T20:40:47.000Z","date":"2024-05-14","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":135.6551,"value":2034826.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $135.00 to $137.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31528,"source":{"system":"sec-edgar","filing":"0000914475-24-000121","document":"wk-form4_1715892031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/wk-form4_1715892031.xml","form_type":"4"}},{"id":1514991,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-16T20:40:47.000Z","date":"2024-05-14","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":73.6,"value":1104000.0,"ownership":{"direct":true},"balance_after":46528,"source":{"system":"sec-edgar","filing":"0000914475-24-000121","document":"wk-form4_1715892031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/wk-form4_1715892031.xml","form_type":"4"}},{"id":1641710,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:27:36.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":8966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":8966,"derivative":{"underlying":"Common Stock","underlying_shares":8966},"source":{"system":"sec-edgar","filing":"0000914475-24-000067","document":"wk-form4_1708036041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000067/wk-form4_1708036041.xml","form_type":"4"}},{"id":1641709,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-02-15T22:27:36.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":45058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":45058,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":45058},"source":{"system":"sec-edgar","filing":"0000914475-24-000067","document":"wk-form4_1708036041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000067/wk-form4_1708036041.xml","form_type":"4"}},{"id":1641708,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:27:36.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":1352,"price":132.8488,"value":179611.5776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15,  2023.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31528,"source":{"system":"sec-edgar","filing":"0000914475-24-000067","document":"wk-form4_1708036041.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000067/wk-form4_1708036041.xml","form_type":"4"}},{"id":1654150,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:12:04.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":980,"price":134.2135,"value":131529.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8 , 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30314,"source":{"system":"sec-edgar","filing":"0000914475-24-000043","document":"wk-form4_1707437515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000043/wk-form4_1707437515.xml","form_type":"4"}},{"id":1654149,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:12:04.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":1280,"price":142.1878,"value":182000.384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6 , 2024 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29434,"source":{"system":"sec-edgar","filing":"0000914475-24-000043","document":"wk-form4_1707437515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000043/wk-form4_1707437515.xml","form_type":"4"}},{"id":1662739,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:00:43.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":1283,"price":140.7161,"value":180538.7563,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,283 shares of common stock issued upon vesting of 2,436 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,153) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.67 to $142.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28284,"source":{"system":"sec-edgar","filing":"0000914475-24-000022","document":"wk-form4_1706918428.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000022/wk-form4_1706918428.xml","form_type":"4"}},{"id":1799008,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-23T23:58:17.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":2132,"price":107.3914,"value":228958.4648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27131,"source":{"system":"sec-edgar","filing":"0001209191-23-047127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047127/doc4.xml","form_type":"4"}},{"id":2014193,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:04:22.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":10264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":10264,"derivative":{"underlying":"Common Stock","underlying_shares":10264},"source":{"system":"sec-edgar","filing":"0001209191-23-009879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009879/doc4.xml","form_type":"4"}},{"id":2014192,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2023-02-16T00:04:22.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":63789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":63789,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":63789},"source":{"system":"sec-edgar","filing":"0001209191-23-009879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009879/doc4.xml","form_type":"4"}},{"id":2026982,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:16:16.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":980,"price":104.1939,"value":102110.022,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.73 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25213,"source":{"system":"sec-edgar","filing":"0001209191-23-007905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007905/doc4.xml","form_type":"4"}},{"id":2026981,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:16:16.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":11491,"price":102.4013,"value":1176693.3383,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the\nReporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from\namending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.93 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24333,"source":{"system":"sec-edgar","filing":"0001209191-23-007905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007905/doc4.xml","form_type":"4"}},{"id":2026980,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:16:16.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":12807,"price":102.4196,"value":1311687.8172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 12,807 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,491) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.06 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":35824,"source":{"system":"sec-edgar","filing":"0001209191-23-007905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007905/doc4.xml","form_type":"4"}},{"id":2026979,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:16:16.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":2030,"price":102.3278,"value":207725.434,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.87 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24333,"source":{"system":"sec-edgar","filing":"0001209191-23-007905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007905/doc4.xml","form_type":"4"}},{"id":2026978,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:16:16.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":1280,"price":105.6667,"value":135253.376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.67 to $107.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22507,"source":{"system":"sec-edgar","filing":"0001209191-23-007905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007905/doc4.xml","form_type":"4"}},{"id":2037149,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-02T21:53:41.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":1283,"price":109.9827,"value":141107.8041,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,283 shares of common stock issued upon vesting of 2,436 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,153) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21357,"source":{"system":"sec-edgar","filing":"0001209191-23-006256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006256/doc4.xml","form_type":"4"}},{"id":2406958,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-09T23:51:40.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":980,"price":79.6506,"value":78057.588,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.08 to $80.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20204,"source":{"system":"sec-edgar","filing":"0001209191-22-008203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008203/doc4.xml","form_type":"4"}},{"id":2406957,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-09T23:51:40.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":1280,"price":80.7782,"value":103396.096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.79 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":19325,"source":{"system":"sec-edgar","filing":"0001209191-22-008203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008203/doc4.xml","form_type":"4"}},{"id":2406956,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-09T23:51:40.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":2030,"price":80.804,"value":164032.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.69 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18175,"source":{"system":"sec-edgar","filing":"0001209191-22-008203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008203/doc4.xml","form_type":"4"}},{"id":2417559,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T00:54:16.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":9745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."}],"balance_after":9745,"derivative":{"underlying":"Common Stock","underlying_shares":9745},"source":{"system":"sec-edgar","filing":"0001209191-22-006583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006583/doc4.xml","form_type":"4"}},{"id":2417558,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2022-02-03T00:54:16.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":66362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":66362,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":66362},"source":{"system":"sec-edgar","filing":"0001209191-22-006583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006583/doc4.xml","form_type":"4"}},{"id":2487149,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:02:53.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1645,"price":82.5851,"value":135852.4895,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 1, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.45 to $85.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16349,"source":{"system":"sec-edgar","filing":"0001209191-21-067870","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121067870/doc4.xml","form_type":"4"}},{"id":2771100,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-03-27T01:48:26.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":49049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":49049,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":49049},"source":{"system":"sec-edgar","filing":"0001209191-21-023367","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023367/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2872976,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:30:30.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":7439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":7439,"derivative":{"underlying":"Common Stock","underlying_shares":7439},"source":{"system":"sec-edgar","filing":"0001209191-21-009132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009132/doc4.xml","form_type":"4"}},{"id":2872975,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-02-10T02:30:30.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":44632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":44632,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":44632},"source":{"system":"sec-edgar","filing":"0001209191-21-009132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009132/doc4.xml","form_type":"4"}},{"id":2872974,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:30:30.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":2030,"price":116.8059,"value":237115.977,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $118.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14869,"source":{"system":"sec-edgar","filing":"0001209191-21-009132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009132/doc4.xml","form_type":"4"}},{"id":2872973,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:30:30.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":880,"price":116.8472,"value":102825.536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 880 shares of common stock issued upon vesting of 2,429 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,549) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.9394 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13043,"source":{"system":"sec-edgar","filing":"0001209191-21-009132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009132/doc4.xml","form_type":"4"}},{"id":2961682,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-02T21:12:36.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":1645,"price":94.6632,"value":155720.964,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 1, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.17 to $94.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":11494,"source":{"system":"sec-edgar","filing":"0001209191-20-061146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120061146/doc4.xml","form_type":"4"}},{"id":2980241,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-16T23:02:09.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2257,"price":90.7444,"value":204810.1108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":10014,"source":{"system":"sec-edgar","filing":"0001209191-20-058532","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058532/doc4.xml","form_type":"4"}},{"id":3065169,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-07T22:22:35.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":2257,"price":118.8994,"value":268355.9458,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding\ntaxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a\nbroker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction\ndate in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan\nsubsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.29 to $120.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":7983,"source":{"system":"sec-edgar","filing":"0001209191-20-045716","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120045716/doc4.xml","form_type":"4"}},{"id":3155169,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-12T00:17:18.000Z","date":"2020-05-07","kind":"exercise","acquired":false,"shares":15000,"price":73.6,"value":1104000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and remaining 75% vesting in 36 equal monthly installments beginning November 1, 2018."}],"balance_after":45000,"derivative":{"exercise_price":73.6,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-028394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120028394/doc4.xml","form_type":"4"}},{"id":3155168,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-12T00:17:18.000Z","date":"2020-05-07","kind":"sale","acquired":false,"shares":15000,"price":110.2089,"value":1653133.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5953,"source":{"system":"sec-edgar","filing":"0001209191-20-028394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120028394/doc4.xml","form_type":"4"}},{"id":3155167,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-12T00:17:18.000Z","date":"2020-05-07","kind":"exercise","acquired":true,"shares":15000,"price":73.6,"value":1104000.0,"ownership":{"direct":true},"balance_after":20953,"source":{"system":"sec-edgar","filing":"0001209191-20-028394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120028394/doc4.xml","form_type":"4"}},{"id":3166828,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-04-30T20:25:05.000Z","date":"2020-04-28","kind":"sale","acquired":false,"shares":1741,"price":102.49,"value":178435.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":5953,"source":{"system":"sec-edgar","filing":"0001209191-20-026302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026302/doc4.xml","form_type":"4"}},{"id":3168661,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-04-29T00:32:32.000Z","date":"2020-04-24","kind":"sale","acquired":false,"shares":1934,"price":99.5175,"value":192466.845,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 252 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020."}],"balance_after":7694,"source":{"system":"sec-edgar","filing":"0001209191-20-026062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026062/doc4.xml","form_type":"4"}},{"id":3280422,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:06:15.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":2030,"price":103.353,"value":209806.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,030 shares of common stock issued upon vesting of 3,855 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,825) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5701,"source":{"system":"sec-edgar","filing":"0001209191-20-008478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008478/doc4.xml","form_type":"4"}},{"id":3285274,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-07T23:40:08.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":9719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."}],"balance_after":9719,"derivative":{"underlying":"Common Stock","underlying_shares":9719},"source":{"system":"sec-edgar","filing":"0001209191-20-007678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007678/doc4.xml","form_type":"4"}},{"id":3285273,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2020-02-07T23:40:08.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":61347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":61347,"derivative":{"exercise_price":102.9,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":61347},"source":{"system":"sec-edgar","filing":"0001209191-20-007678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007678/doc4.xml","form_type":"4"}},{"id":3353107,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-12-04T23:06:26.000Z","date":"2019-12-02","kind":"sale","acquired":false,"shares":1645,"price":116.3285,"value":191360.3825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 2, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from\namending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.92 to $117.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes a total of 449 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 329 shares on February 28, 2019 and 120 shares on August 30, 2019."}],"balance_after":3876,"source":{"system":"sec-edgar","filing":"0001209191-19-059146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119059146/doc4.xml","form_type":"4"}},{"id":3669068,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-02-08T22:04:55.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":15423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."}],"balance_after":15423,"derivative":{"underlying":"Common Stock","underlying_shares":15423},"source":{"system":"sec-edgar","filing":"0001209191-19-008625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008625/doc4.xml","form_type":"4"}},{"id":3669067,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2019-02-08T22:04:55.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":83341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":83341,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":83341},"source":{"system":"sec-edgar","filing":"0001209191-19-008625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008625/doc4.xml","form_type":"4"}},{"id":3742327,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-06T22:54:52.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":1178,"price":89.9997,"value":106019.6466,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,178 shares of common stock issued upon vesting of 3,125 restricted stock units on December 3, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,947) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in\na Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from\namending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $89.8493 to $90.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1947,"source":{"system":"sec-edgar","filing":"0001209191-18-061372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118061372/doc4.xml","form_type":"4"}},{"id":4072676,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-07T22:59:50.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Performance Restricted Stock Units (\"PRSU\") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine."}],"balance_after":12250,"derivative":{"expiration_date":"2020-02-05","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-18-008205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008205/doc4.xml","form_type":"4"}},{"id":4072675,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-07T22:59:50.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period."}],"balance_after":12250,"derivative":{"expiration_date":"2021-03-15","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-18-008205","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008205/doc4.xml","form_type":"4"}},{"id":4143118,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2017-12-05T21:24:56.000Z","date":"2017-12-01","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-17-063918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117063918/doc4.xml","form_type":"4"}},{"id":4143117,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2017-12-05T21:24:56.000Z","date":"2017-12-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on December 1, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":60000,"derivative":{"exercise_price":73.6,"expiration_date":"2027-12-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-063918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117063918/doc4.xml","form_type":"4"}}]}